European Society of Cardiology (ESC) Congress 2019 & World Congress of Cardiology (WCC) 2019

New ESC guidelines zero in on lipids, diabetes, and more

Roshini Claire Anthony, Elvira Manzano, 20191001070306

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

New guidelines: Paradigm shift in CV management of T2D patients

Roshini Claire Anthony, 20190927140302

Recently published cardiovascular outcome trials (CVOTs) in patients with diabetes (DM) have led to updates in the management of cardiovascular disease (CVD) in DM patients. These updates were reflected in the 2019 ESC guidelines on diabetes, prediabetes, and CVD, a collaboration between ESC and EASD*.

Podcast: Prof Salim Yusuf shares insight on sodium intake, one of the modifiable risk factors of CVD

20190924065244

Podcast: Prof Salim Yusuf shares insight on sodium intake, one of the modifiable risk factors of CVD

Diabetes a risk factor for heart failure post-MI

Elaine Soliven, 20190923031307

Patients with diabetes are more likely to have an increased risk of developing heart failure (HF) after an acute myocardial infarction (MI) compared with those without diabetes, according to the Fast-MI* study presented at ESC 2019.

High-dose valsartan reduces systolic BP in children with hypertension

Elaine Soliven, 20190923000000

Treatment with a higher rather than a lower dose of valsartan led to significantly greater reductions in systolic blood pressure (BP) in children with hypertension, regardless of their chronic kidney disease (CKD) status, according to a study presented at ESC 2019.

SYNTAXES: CABG preferable to PCI in multivessel disease

Roshini Claire Anthony, 20190920140202

The mortality rate for patients who undergo percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for de-novo three-vessel disease or left main coronary artery disease (CAD) is comparable at 10 years. However, CABG may be preferable for those with three-vessel disease, according to the SYNTAX Extended Survival (SYNTAXES) study, a 10-year follow-up of the SYNTAX* trial.

Ticagrelor displays net clinical benefit in GLOBAL LEADERS

Audrey Abella, 20190920100000

Subgroup evaluations of the GLOBAL LEADERS trial demonstrated the anti-ischaemic efficacy of long-term ticagrelor monotherapy relative to aspirin monotherapy in patients who had percutaneous coronary intervention (PCI). However, this occurred at the expense of bleeding in the elderly.

Unexpected win for prasugrel in ACS

Audrey Abella, 20190917100000

The potent P2Y12 inhibitor prasugrel significantly reduced the incidence of death, myocardial infarction (MI), or stroke in patients with acute coronary syndrome (ACS) with or without ST-segment elevation (STE) compared with ticagrelor, according to the results of the ISAR-REACT* 5 trial presented at ESC Congress 2019. Moreover, the improved anti-ischaemic efficacy of prasugrel was not accompanied by an increased bleeding risk.

Studies reveal gaps in LDL-C management in patients with high CV risk

Christina Lau, 20190917085943

Significant therapeutic gaps exist in LDL-cholesterol (LDL-C) management among patients with high cardiovascular (CV) risk in Hong Kong, according to two studies reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.

Single testing with high-sensitivity troponin effective, safe for early rule-out of MI

Pearl Toh, 20190916190000

A single testing of cardiac troponin I using a high-sensitivity assay can effectively rule out myocardial infarction (MI) without compromising safety, according to the HiSTORIC* study presented at the ESC 2019 Congress.